CoChat
Sign Up
Cited by 87Cardiac Arrhythmias and TreatmentsHealth Systems, Economic Evaluations, Quality of LifeAtrial Fibrillation Management and Outcomes

The DOI matches its Crossref record; 77 of the 77 references it cites were found in a registry or an index.

Cost-Effectiveness of Radiofrequency Ablation for Supraventricular Tachycardia

Cheng, Carol H.F., Sanders, Gillian D., Hlatky, Mark A., Heidenreich, Paul, McDonald, Kathryn M., Lee, Byron K., Larson, Mary S., Owens, Douglas K.·2000·Annals of Internal Medicine
DOI 10.7326/0003-4819-133-11-200012050-00010
Open this paper in CoChat — free account

Abstract

BACKGROUND: Radiofrequency ablation is an established but expensive treatment option for many forms of supraventricular tachycardia. Most cases of supraventricular tachycardia are not life-threatening; the goal of therapy is therefore to improve the patient's quality of life. OBJECTIVE: To compare the cost-effectiveness of radiofrequency ablation with that of medical management of supraventricular tachycardia. DESIGN: Markov model. DATA SOURCES: Costs were estimated from a major academic hospital and the literature, and treatment efficacy was estimated from reports from clinical studies at major medical centers. Probabilities of clinical outcomes were estimated from the literature. To account for the effect of radiofrequency ablation on quality of life, assessments by patients who had undergone the procedure were used. TARGET POPULATION: Cohort of symptomatic patients who experienced 4.6 unscheduled visits per year to an emergency department or a physician's office while receiving long-term drug therapy for supraventricular tachycardia. TIME HORIZON: Patient lifetime. PERSPECTIVE: Societal. INTERVENTIONS: Initial radiofrequency ablation, long-term antiarrhythmic drug therapy, and treatment of acute episodes of arrhythmia with antiarrhythmic drugs. OUTCOME MEASURES: Costs, quality-adjusted life-years, life-years, and marginal cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Among patients who have monthly episodes of supraventricular tachycardia, radiofrequency ablation was the most effective and least expensive therapy and therefore dominated the drug therapy options. Radiofrequency ablation improved quality-adjusted life expectancy by 3.10 quality-adjusted life-years and reduced lifetime medical expenditures by $27 900 compared with long-term drug therapy. Long-term drug therapy was more effective and had lower costs than episodic drug therapy. RESULTS OF SENSITIVITY ANALYSIS: The findings were highly robust over substantial variations in assumptions about the efficacy and complication rate of radiofrequency ablation, including analyses in which the complication rate was tripled and efficacy was decreased substantially. CONCLUSIONS: Radiofrequency ablation substantially improves quality of life and reduces costs when it is used to treat highly symptomatic patients. Although the benefit of radiofrequency ablation has not been studied in less symptomatic patients, a small improvement in quality of life is sufficient to give preference to radiofrequency ablation over drug therapy.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-133-11-200012050-00010

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 7

  1. Talwar KK, 1996, Indian Heart J, 48, 685
  2. Thakur RK, 1994, Can J Cardiol, 10, 835
  3. Hindricks G, 1996, Eur Heart J, 17, 82
  4. 1995, Circulation, 92, 2550
  5. Krikler DM, 1988, Prog Clin Biol Res, 275, 301
  6. Prystowsky EN, 1994, Clin Cardiol, 17, II7
  7. Scheinman M, 1994, Clin Cardiol, 17, II11

Cited by

Sorted by citations

See all 87

Related

See all

Metadata

Authors
Cheng, C. H. F., Sanders, G. D., Hlatky, M. A., Heidenreich, P., McDonald, K. M., Lee, B. K., Larson, M. S., & Owens, D. K.
Affiliations
VA Palo Alto Health Care System (US)
ORCID
Venue
Annals of Internal Medicine
Publisher
American College of Physicians
Published
2000-12-05
Volume
133
Issue
11
Pages
864-876
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
DOI
10.7326/0003-4819-133-11-200012050-00010
OpenAlex
W1972421012
Cited by
87
References
77
Citations by year
2026: 1 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 4 · 2020: 6 · 2019: 3 · 2018: 2 · 2017: 2 · 2016: 6 · 2015: 8 · 2013: 2 · 2012: 5
FWCI
3.21
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
Agency for Healthcare Research and Quality (HS08362)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Arrhythmias and Treatments
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Keywords
radiofrequency ablation, supraventricular tachycardia, cost-effectiveness, antiarrhythmic therapy, quality-adjusted life years, quality of life, medical management
MeSH terms
Adult, Aged, Anti-Arrhythmia Agents, Cost-Benefit Analysis, Decision Trees, Direct Service Costs, Heart Block, Humans, Markov Chains, Middle Aged, Sensitivity and Specificity, Tachycardia, Supraventricular, Drug Costs, Catheter Ablation, Quality-Adjusted Life Years

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review